Status:
COMPLETED
Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
Lead Sponsor:
Pfizer
Conditions:
Non-Alcoholic Steatohepatitis(NASH)
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treatment for non-...
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) of 25 to 40 kg/m2
- Subjects with biopsy evidence of NASH in the 2 years prior to the screening visit.
- Hemoglobin ≥11 g/dL, platelet count ≥100,000 cells/mm3, neutrophil count ≥1,500cells/mm3.
Exclusion
- Other forms than NASH liver disease.
- Decompensated or severe liver disease.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00706537
Start Date
July 1 2008
End Date
November 1 2008
Last Update
August 13 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anaheim, California, United States, 92801
2
Pfizer Investigational Site
Anaheim, California, United States, 92804
3
Pfizer Investigational Site
Durham, North Carolina, United States, 27710